Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multiple-dose study of SV003 in adolescents and adults with hemophilia A with or without inhibitors
CTR20262743Phase 2Active
- Sponsor
- Xunyao Biotech
- Start
- Jul 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SV003 in hemophilia A, sponsored by Xunyao Biotech. Started Jul 2026; status: active.
02
Drugs
SV003
03
Conditions
hemophilia A
Beyond the preview
Go deeper on CTR20262743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262743.